Novugen's core purpose and primary source of innovation lie in our R&D efforts. Situated in the heart of Southeast Asia, our global R&D center in Malaysia, led by highly experienced scientists, is dedicated to developing challenging and technology-intensive products, including complex generics meeting USFDA standards.
We have full capabilities to handle development services for a variety of dosage forms including:
Tablets, capsules and powders
Pellets and beads
Liquids, solutions, suspensions and emulsions
Soft Gel capsules
Parental Dosage Forms (Liquid and Lyophilized powders)
Granules for reconstitution
Drug in capsule/vial for clinical trials
Other Novel dosage forms(e.g MUPS, OCAS, DDR , etc.)
Explore Our CDONovugen invests in cutting-edge technologies and experienced scientists for developing challenging and technology-intensive products. Our advanced labs and research center in Malaysia, specializing in oncology and other therapeutic areas, facilitate solid-state characterization for API and Finished Products, ensuring equivalence with the brand product. This allows us to successfully pass bioequivalence studies with EU and USFDA-approved Clinical Research Organizations.